SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-187841
Filing Date
2021-06-10
Accepted
2021-06-10 16:39:08
Documents
12
Period of Report
2021-06-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d156935d8k.htm   iXBRL 8-K 44170
  Complete submission text file 0001193125-21-187841.txt   169091

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA clvs-20210610.xsd EX-101.SCH 3088
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20210610_lab.xml EX-101.LAB 18139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20210610_pre.xml EX-101.PRE 11420
5 EXTRACTED XBRL INSTANCE DOCUMENT d156935d8k_htm.xml XML 3356
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 211008588
SIC: 2834 Pharmaceutical Preparations